Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-577-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees59
OptionableNot Optionable
Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions
What is Evelo Biosciences' stock symbol?
Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."
How were Evelo Biosciences' earnings last quarter?
Evelo Biosciences Inc (NASDAQ:EVLO) posted its quarterly earnings results on Thursday, February, 14th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.09. View Evelo Biosciences' Earnings History.
When is Evelo Biosciences' next earnings date?
What price target have analysts set for EVLO?
5 analysts have issued twelve-month target prices for Evelo Biosciences' shares. Their predictions range from $10.00 to $30.00. On average, they expect Evelo Biosciences' stock price to reach $22.75 in the next twelve months. This suggests a possible upside of 134.3% from the stock's current price. View Analyst Price Targets for Evelo Biosciences.
What is the consensus analysts' recommendation for Evelo Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evelo Biosciences.
Has Evelo Biosciences been receiving favorable news coverage?
Press coverage about EVLO stock has trended somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evelo Biosciences earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are some of Evelo Biosciences' key competitors?
Some companies that are related to Evelo Biosciences include Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Homology Medicines (FIXX), CannTrust (CNTTF), Advanz Pharma (CXRXF) and Retrophin (RTRX).
Who are Evelo Biosciences' key executives?
Evelo Biosciences' management team includes the folowing people:
- Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)
- Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)
- Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)
- Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)
- Mr. Jonathan Poole, Chief Financial Officer (Age 44)
When did Evelo Biosciences IPO?
(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
Who are Evelo Biosciences' major shareholders?
Evelo Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.11%), Northern Trust Corp (0.40%), Geode Capital Management LLC (0.28%), Victory Capital Management Inc. (0.28%), Bank of New York Mellon Corp (0.12%) and Jane Street Group LLC (0.06%). View Institutional Ownership Trends for Evelo Biosciences.
Which major investors are selling Evelo Biosciences stock?
Which major investors are buying Evelo Biosciences stock?
EVLO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, Essex Investment Management Co. LLC, Essex Investment Management Co. LLC, Larson Financial Group LLC and American International Group Inc.. View Insider Buying and Selling for Evelo Biosciences.
How do I buy shares of Evelo Biosciences?
Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evelo Biosciences' stock price today?
One share of EVLO stock can currently be purchased for approximately $9.71.
How big of a company is Evelo Biosciences?
Evelo Biosciences has a market capitalization of $308.48 million. Evelo Biosciences employs 59 workers across the globe.
What is Evelo Biosciences' official website?
How can I contact Evelo Biosciences?
Evelo Biosciences' mailing address is 620 Memorial Drive Suite 200 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]
MarketBeat Community Rating for Evelo Biosciences (NASDAQ EVLO)
MarketBeat's community ratings are surveys of what our community members think about Evelo Biosciences and other stocks. Vote "Outperform" if you believe EVLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
